Stockreport

CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination with KEYTRUDA® (pembrolizumab) [Yahoo! Finance]

CytomX Therapeutics, Inc.  (CTMX) 
Last cytomx therapeutics, inc. earnings: 11/7 04:09 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.cytomx.com
PDF - Phase 1 first-in-human study expected to start in first half of 2024 - - Clinical trial will evaluate CX-801 as monotherapy and in combination with KEYTRUDA in pati [Read more]